Article
Oncology
Yiyang Li, Huimin An, Chuan Shen, Boqian Wang, Ting Zhang, Yifan Hong, Hui Jiang, Peijun Zhou, Xianting Ding
Summary: FK506 and RAPA have different effects on T-cell lineages after transplantation, leading to different immune responses and transplant outcomes. Long-term RAPA treatment can reduce the occurrence of tumors and infections.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Asmae Belhaj, Laurence Dewachter, Astrid Monier, Gregory Vegh, Sandrine Rorive, Myriam Remmelink, Melanie Closset, Christian Melot, Jacques Creteur, Isabelle Salmon, Benoit Rondelet
Summary: Tacrolimus can prevent right ventricular dysfunction caused by brain death by inhibiting apoptosis and inflammation activation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Ophthalmology
Sally L. Painter, Mrinal Rana, Ankur Barua, Joseph Abbott, Girish Gupte, Sunil Shah, Manoj Parulekar
Summary: This study reported the outcomes of tacrolimus immunosuppression after PK in very young children, showing higher 1-year graft survival rates for primary PK, but mainly attributed to failures such as infection, rejection, and glaucoma. The failure rate was higher for repeat PK, but overall graft survival rates were comparable to the literature.
Article
Chemistry, Medicinal
Ji Hwan Lee, Musun Park, Kiwon Jung, Gyeongmin Hong, Hye Lim Lee, Dong-Wook Kim, Chang-Eop Kim, Ki Sung Kang
Summary: Gallic acid was found to increase cell survival and protect against nephrotoxicity induced by FK506. Its protective effect was strongest among the compounds tested and was further confirmed in a rat model. Molecular docking and bioavailability investigations provided supporting evidence for the nephroprotective function of gallic acid.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Medical Laboratory Technology
Yoana Aurelia Djaelani, Thomas Giese, Claudia Sommerer, David Czock
Summary: Therapeutic drug monitoring of calcineurin inhibitor (CNI) concentrations is routinely performed in clinical practice, but the effects of CNIs can vary among patients with identical concentrations. The quantification of nuclear factor of activated T-cell-regulated gene expression (NFAT-RGE) is a promising method for measuring individual CNI effects, but CNI pharmacodynamics are not fully understood.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Medical Laboratory Technology
Marith Francke, Louise M. Andrews, Hoang Lan Le, Daan van de Velde, Marjolein Dieterich, Suwasin Udomkarnjananun, Marian C. Clahsen-van Groningen, Carla C. Baan, Teun van Gelder, Brenda C. M. de Winter, Dennis A. Hesselink
Summary: In the early phase after kidney transplantation, the exposure and distribution of tacrolimus appear stable. The tacrolimus concentration within peripheral blood mononuclear cells does not have a significant association with the occurrence of rejection.
CLINICAL BIOCHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Xiaoying He, Xi Yang, Xiaoting Yan, Mingzhu Huang, Zheng Xiang, Yan Lou
Summary: The study found that T lymphocytes' pharmacodynamic response to tacrolimus was closely related to renal function and the prognosis of renal transplant patients. Metabolomic analysis identified potential biomarkers that could predict the efficacy of tacrolimus. Pathway and logistic regression analysis revealed the mechanism of individual variation and provided a basis for personalized drug therapy.
Article
Pharmacology & Pharmacy
Claudia Sommerer, Merce Brunet, Klemens Budde, Olga Millan, Lluis Guirado Perich, Petra Glander, Stefan Meuer, Martin Zeier, Thomas Giese
Summary: NFAT-regulated gene expression serves as a potential noninvasive predictive biomarker in Tac-treated renal allograft recipients, helping to detect patients at risk of acute rejection and infectious complications. High residual gene expression is associated with an increased risk of acute rejection, while low residual gene expression is linked to a higher incidence of viral complications, such as cytomegalovirus and BK virus replication. Monitoring NFAT-RGE provides additional useful information for physicians to achieve personalized Tac treatment.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Medicine, Research & Experimental
Milosz Miedziaszczyk, Ilona Idasiak-Piechocka
Summary: Tacrolimus and omeprazole are commonly used drugs in kidney transplant patients. However, simultaneous administration may lead to drug interactions, affecting the pharmacokinetics of tacrolimus and potentially causing adverse reactions. It is important to address these interactions and find appropriate solutions.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Lekshmy Srinivas, Noble Gracious, Radhakrishnan R. Nair
Summary: Tacrolimus is an immunosuppressant used in solid organ transplantation. This study in South Indian renal transplant recipients investigated the effects of gene polymorphisms on tacrolimus concentrations and adverse effects. The findings suggest that genotype-guided initial dosing of tacrolimus can help achieve optimal drug levels and prevent adverse effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yilei Yang, Xin Huang, Yinping Shi, Rui Yang, Haiyan Shi, Xinmei Yang, Guoxiang Hao, Yi Zheng, Jianning Wang, Lequn Su, Yan Li, Wei Zhao
Summary: A CYP3A5 genotype-dependent drug-drug interaction was found between tacrolimus and nifedipine in Chinese renal transplant patients. Personalized therapy accounting for CYP3A5 genotype detection and therapeutic drug monitoring is necessary for these patients receiving tacrolimus and nifedipine treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Ting Chen, Qi Zhang, Nianhai Zhang, Bo Liu, Junying Chen, Fei Huang, Jianhua Lin, Ruilong Lan, Xianhe Xie, Zili Wang
Summary: This study found that intermittent administration of tacrolimus can inhibit tumor growth, facilitate the infiltration of CD8+T cells, and suppress the transcription of exhaustion-related genes such as Nr4a1 and Ctla4 in melanoma-bearing mice, suggesting that blocking TCR signal intermittently is a promising approach to defer the developmental process of T cell exhaustion.
Article
Immunology
Bo Peng, Min Yang, Quan Zhuang, Junhui Li, Pengpeng Zhang, Hong Liu, Ke Cheng, Yingzi Ming
Summary: This study standardized the measurement of nCD64 and mHLA-DR using MESF, and evaluated their role in immune monitoring for kidney transplant recipients (KTRs) with infection. The standardized values of nCD64 and mHLA-DR showed good diagnostic performance for infection and sepsis, respectively, and could contribute to individualized treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biology
Dagmara Szypulska-Koziarska, Aleksandra Wilk, Malgorzata Marchelek-Mysliwiec, Daria Sleboda-Taront, Barbara Wiszniewska
Summary: Renal transplant recipients need lifelong immunosuppressive therapy, which can affect the hormonal balance of sex hormones in both men and women. A tacrolimus-based immunosuppressive regimen may lead to hormonal imbalance that influences fertility, so careful consideration is needed when choosing the treatment plan for reproductive-age recipients.
Article
Pharmacology & Pharmacy
Benedetta C. Sallustio, Benjamin D. Noll, Rong Hu, Daniel T. Barratt, Jonathan Tuke, Janet K. Coller, Graeme R. Russ, Andrew A. Somogyi
Summary: Recipient and donor CYP3A5 and ABCB1 3435C>T genotypes do not determine allograft tacrolimus exposure in kidney transplant recipients. However, tacrolimus dose and C-0Blood are significant predictors of C-Graft, and the relationship between C-0Blood and C-Graft appears to differ in the presence or absence of acute nephrotoxicity.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)